Diamyd Medical AB logo

DMYD B - Diamyd Medical AB Share Price

SEK29.9 3.5  13.3%

Last Trade - 5:00pm

Sector
Healthcare
Size
Small Cap
Market Cap £160.0m
Enterprise Value £152.9m
Revenue £33.4k
Position in Universe 656th / 1782
Bullish
Bearish
Unlock DMYD B Revenue
Momentum
Relative Strength (%)
1m +32.4%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -1.31%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Aug 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.44 0.51 0.76 0.92 0.73 1.57 52.0 2.00 +28.8%
+231.3
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 31 May 2020, Diamyd Medical AB revenues decreased 80% to SEK263K. Net income totaled SEK23.2M vs. loss of SEK26.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net Income reflects External research and development costs decrease of 54% to SEK7.5M (expense), Other Operating Income increase from SEK56K to SEK770K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

DMYD B Revenue Unlock DMYD B Revenue

Net Income

DMYD B Net Income Unlock DMYD B Revenue

Normalised EPS

DMYD B Normalised EPS Unlock DMYD B Revenue

PE Ratio Range

DMYD B PE Ratio Range Unlock DMYD B Revenue

Dividend Yield Range

DMYD B Dividend Yield Range Unlock DMYD B Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
DMYD B EPS Forecasts Unlock DMYD B Revenue
Profile Summary

Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.

Directors
Last Annual August 31st, 2019
Last Interim May 31st, 2020
Public Since May 20, 2013
No. of Shareholders: n/a
No. of Employees: 7
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 69,169,796
Free Float (0.0%)
Eligible for
ISAs
SIPPs
DMYD B Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for DMYD B
Upcoming Events for DMYD B
Frequently Asked Questions for Diamyd Medical AB
What is the Diamyd Medical AB share price?

As of 5:00pm, shares in Diamyd Medical AB are trading at SEK29.9, giving the company a market capitalisation of £160.0m. This share price information is delayed by 15 minutes.

How has the Diamyd Medical AB share price performed this year?

Shares in Diamyd Medical AB are currently trading at SEK29.9 and the price has moved by 0.206k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Diamyd Medical AB price has moved by 0.218k% over the past year.

What are the analyst and broker recommendations for Diamyd Medical AB?

Of the analysts with advisory recommendations for Diamyd Medical AB, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Diamyd Medical AB is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Diamyd Medical AB next release its financial results?

Diamyd Medical AB is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-05-31
What is the Diamyd Medical AB dividend yield?

Diamyd Medical AB does not currently pay a dividend.

Does Diamyd Medical AB pay a dividend?

Diamyd Medical AB does not currently pay a dividend.

When does Diamyd Medical AB next pay dividends?

Diamyd Medical AB does not currently pay a dividend.

How do I buy Diamyd Medical AB shares?

To buy shares in Diamyd Medical AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Diamyd Medical AB?

Shares in Diamyd Medical AB are currently trading at SEK29.9, giving the company a market capitalisation of £160.0m.

Where are Diamyd Medical AB shares listed? Where are Diamyd Medical AB shares listed?

Here are the trading details for Diamyd Medical AB:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: DMYD B
What kind of share is Diamyd Medical AB?

Based on an overall assessment of its quality, value and momentum, Diamyd Medical AB is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Diamyd Medical AB share price forecast 2020?

We were not able to load any forecast data for Diamyd Medical AB.

How can I tell whether the Diamyd Medical AB share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Diamyd Medical AB. Over the past six months, the relative strength of its shares against the market has been 64.77%. At the current price of SEK29.9, shares in Diamyd Medical AB are trading at 59.33% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Diamyd Medical AB PE Ratio?

The Diamyd Medical AB PE ratio based on its reported earnings over the past 12 months is 0.111k. The shares are currently trading at SEK29.9.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Diamyd Medical AB?

Diamyd Medical AB's management team is headed by:

Anders Essen-Moller - DRC
Maria-Teresa Essen-Moller - DRC
Erik Nerpin - CHM
Anna Styrud - CFO
Ulf Hannelius - CEO
Martina Widman - OTH
Torbjorn Backstrom - DRC
Mark Atkinson - DRC
Who are the major shareholders of Diamyd Medical AB?

Here are the top five shareholders of Diamyd Medical AB based on the size of their shareholding:

Similar to DMYD B
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.